Research ArticleArticle
International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor
Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4
Charles Brink
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Sven-Erik Dahlén
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Jeffrey Drazen
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Jilly F. Evans
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Douglas W. P. Hay
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
G. Enrico Rovati
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Charles N. Serhan
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Takao Shimizu
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
Takehiko Yokomizo
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor
Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 1, 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4
Research ArticleArticle
International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor
Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 1, 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement